When it comes to people with obesity and without diabetes, the 2025 AACE guidelines recommend semaglutide and tirzepatide as first line over other drug classes for a variety of conditions, including those with prediabetes, type 2 diabetes, osteoarthritis, kidney disease, heart failure, fatty liver, cardiovascular protection, and sleep apnea
Szraz s hvs helyen troland, fnytl vdve
The weight loss labeled Saxenda will not have its generic launch for another 2-3 years, so utilization management will need to be considered
Tricyclics (amitriptyline, nortriptyline) carried the greatest cardiometabolic burden
For these women, the waiting period before starting GLP-1 treatment can feel especially frustrating